GSK-Dr Reddy's JV eyes 1st product in Europe this year

In 2009, GSK had signed agreement with DRL giving it access to over 100 future generic drugs

UK-based health company GlaxoSmithKline (GSK) today said its joint venture with Hyderabad’s generics manufacturer Dr Reddy’s Laboratories Limited would license its first product in Europe sometime during this calender year.

“We (the JV) have a very strong product pipeline ... we are focused on filing for registrations of these in Europe. These products, which will take at least two years from the time of registration for commercial launch, will however be aimed at emerging markets like Mexico and Brazil,” said Rogerio Ribero, senior vice president and area head (emerging markets - Asia-Pacific), GSK.

Ribero was speaking to mediapersons on the sidelines of the 11th edition of BioAsia, a three-day global bio-business forum, here on Tuesday.